239 related articles for article (PubMed ID: 26828900)
1. A novel bispecific antibody, BiSS, with potent anti-cancer activities.
Dong B; Zhou C; He P; Li J; Chen S; Miao J; Li Q; Wang Z
Cancer Biol Ther; 2016 Apr; 17(4):364-70. PubMed ID: 26828900
[TBL] [Abstract][Full Text] [Related]
2. Single domain antibody-based bispecific antibody induces potent specific anti-tumor activity.
Li J; Zhou C; Dong B; Zhong H; Chen S; Li Q; Wang Z
Cancer Biol Ther; 2016 Dec; 17(12):1231-1239. PubMed ID: 27645568
[TBL] [Abstract][Full Text] [Related]
3. Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies.
Zhao Y; Li Y; Wu X; Li L; Liu J; Wang Y; Liu Y; Li Q; Wang Z
Cancer Biol Ther; 2020; 21(1):72-80. PubMed ID: 31564196
[TBL] [Abstract][Full Text] [Related]
4. A novel bispecific antibody, S-Fab, induces potent cancer cell killing.
Li L; He P; Zhou C; Jing L; Dong B; Chen S; Zhang N; Liu Y; Miao J; Wang Z; Li Q
J Immunother; 2015; 38(9):350-6. PubMed ID: 26448579
[TBL] [Abstract][Full Text] [Related]
5. Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells.
Li Y; Zhou C; Li J; Liu J; Lin L; Li L; Cao D; Li Q; Wang Z
PLoS One; 2018; 13(1):e0191024. PubMed ID: 29357376
[TBL] [Abstract][Full Text] [Related]
6. Incorporation of a Novel CD16-Specific Single-Domain Antibody into Multispecific Natural Killer Cell Engagers With Potent ADCC.
van Faassen H; Jo DH; Ryan S; Lowden MJ; Raphael S; MacKenzie CR; Lee SH; Hussack G; Henry KA
Mol Pharm; 2021 Jun; 18(6):2375-2384. PubMed ID: 33999642
[TBL] [Abstract][Full Text] [Related]
7. Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells.
Rozan C; Cornillon A; Pétiard C; Chartier M; Behar G; Boix C; Kerfelec B; Robert B; Pèlegrin A; Chames P; Teillaud JL; Baty D
Mol Cancer Ther; 2013 Aug; 12(8):1481-91. PubMed ID: 23757164
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma.
Zou J; Chen D; Zong Y; Ye S; Tang J; Meng H; An G; Zhang X; Yang L
Cancer Sci; 2015 May; 106(5):512-21. PubMed ID: 25664501
[TBL] [Abstract][Full Text] [Related]
9. Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy.
Pan H; Liu J; Deng W; Xing J; Li Q; Wang Z
Int J Nanomedicine; 2018; 13():3189-3201. PubMed ID: 29881272
[TBL] [Abstract][Full Text] [Related]
10. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
11. A trivalent anti-erbB2/anti-CD16 bispecific antibody retargeting NK cells against human breast cancer cells.
Xie Z; Shi M; Feng J; Yu M; Sun Y; Shen B; Guo N
Biochem Biophys Res Commun; 2003 Nov; 311(2):307-12. PubMed ID: 14592414
[TBL] [Abstract][Full Text] [Related]
12. A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity.
Wang Y; Liu J; Pan H; Xing J; Wu X; Li Q; Wang Z
J Vis Exp; 2018 Jul; (137):. PubMed ID: 30059039
[TBL] [Abstract][Full Text] [Related]
13. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M
Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201
[TBL] [Abstract][Full Text] [Related]
14. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
15. A bispecific nanobody targeting the dimerization interface of epidermal growth factor receptor: Evidence for tumor suppressive actions in vitro and in vivo.
Xu Z; Qiu C; Wen B; Wang S; Zhu L; Zhao L; Li H
Biochem Biophys Res Commun; 2021 Apr; 548():78-83. PubMed ID: 33636638
[TBL] [Abstract][Full Text] [Related]
16. A novel targeted GPC3/CD3 bispecific antibody for the treatment hepatocellular carcinoma.
Yu L; Yang X; Huang N; Lang QL; He QL; Jian-Hua W; Liang-Peng G
Cancer Biol Ther; 2020 Jul; 21(7):597-603. PubMed ID: 32240054
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of action of a T cell-dependent bispecific antibody as a breakthrough immunotherapy against refractory colorectal cancer with an oncogenic mutation.
Kamakura D; Asano R; Kawai H; Yasunaga M
Cancer Immunol Immunother; 2021 Jan; 70(1):177-188. PubMed ID: 32666260
[TBL] [Abstract][Full Text] [Related]
18. A Bispecific Antibody Based on Pertuzumab Fab Has Potent Antitumor Activity.
Deng W; Liu J; Pan H; Li L; Zhou C; Wang X; Shu R; Dong B; Cao D; Li Q; Wang Z
J Immunother; 2018 Jan; 41(1):1-8. PubMed ID: 29232309
[TBL] [Abstract][Full Text] [Related]
19. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
[TBL] [Abstract][Full Text] [Related]
20. Bispecific antibodies in cancer immunotherapy.
Chen S; Li J; Li Q; Wang Z
Hum Vaccin Immunother; 2016 Oct; 12(10):2491-2500. PubMed ID: 27249163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
